BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37182130)

  • 1. Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer.
    Liang X; Chen X; Li H; Li Y
    Front Oncol; 2023; 13():1113374. PubMed ID: 37182130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis.
    Li Y; Liang X; Yang T; Guo S; Chen X
    Front Oncol; 2022; 12():878054. PubMed ID: 36226060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer.
    Liang X; Chen X; Li H; Li Y
    Front Public Health; 2023; 11():1156427. PubMed ID: 37727602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer.
    Lang Y; Lin Y; Deng M; Liu X
    BMC Cancer; 2024 Feb; 24(1):236. PubMed ID: 38383374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cemiplimab combined with chemotherapy
    Zhu G; Cai H; Zheng Z
    Ther Adv Med Oncol; 2023; 15():17588359231213619. PubMed ID: 38028144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
    Kuznik A; Smare C; Chen CI; Venkatachalam M; Keeping S; Atsou K; Xu Y; Wilson F; Guyot P; Chan K; Glowienka E; Konidaris G
    Value Health; 2022 Feb; 25(2):203-214. PubMed ID: 35094793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line Cemiplimab versus Standard Chemotherapy in Advanced Non-small Cell Lung Cancer Patients with at Least 50% Programmed Cell Death Receptor Ligand-1 Positivity: Analysis of Cost-effectiveness.
    Zhang M; Liu X; Wen F; Wu Q; Zhou K; Bai L; Li Q
    Clin Oncol (R Coll Radiol); 2022 Mar; 34(3):e123-e129. PubMed ID: 34736841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
    Liang X; Chen X; Li H; Liu X; Li Y
    Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.
    Liang X; Chen X; Li H; Li Y
    Front Public Health; 2023; 11():1009920. PubMed ID: 36794070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer.
    Lu T; Huang Y; Cai Z; Lin W; Chen X; Chen R; Hu Y
    Front Pharmacol; 2023; 14():1171302. PubMed ID: 37564176
    [No Abstract]   [Full Text] [Related]  

  • 11. Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Li Y; Liang X; Li H; Yang T; Guo S; Chen X
    Front Pharmacol; 2022; 13():906956. PubMed ID: 35928269
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
    Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
    Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50.
    Wang L; Peng Y; Zeng X; Peng L; Li S; Qin S; Wan X; Tan C
    Adv Ther; 2021 Aug; 38(8):4354-4365. PubMed ID: 34241780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Shi D; Li Y; Liang X; Chen L
    Front Oncol; 2023; 13():1162360. PubMed ID: 37251935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.
    Liu Q; Zhou Z; Luo X; Yi L; Peng L; Wan X; Tan C; Zeng X
    Front Pharmacol; 2021; 12():788569. PubMed ID: 34992538
    [No Abstract]   [Full Text] [Related]  

  • 16. Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy.
    Ghetti G; D'Avella MC; Pradelli L
    Clinicoecon Outcomes Res; 2021; 13():121-133. PubMed ID: 33603419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
    Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer.
    Li Y; Hu M; Zhang Z; Chu M; Xu R; Liu L; Dong W; Yang M; Zhang R
    Cancer Med; 2024 Jan; 13(1):. PubMed ID: 38186268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China.
    Liu H; Wang Y; He Q
    Health Econ Rev; 2022 Dec; 12(1):66. PubMed ID: 36581793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis.
    Liu K; Zhu Y; Zhou Y; Zhu H
    Adv Ther; 2023 Apr; 40(4):1838-1849. PubMed ID: 36870042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.